Rybrevant™ (amivantamab-vmjw) – New drug approval
May 21, 2021 - Johnson & Johnson announced the FDA approval of Rybrevant (amivantamab-vmjw), for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Top